Editorial: Anakoinosis: An Innovative Anticancer Therapy Targeting the Aberrant Cancer Tissue Homeostasis

Daniel Heudobler¹, Albrecht Reichle¹* and Lina Ghibelli²

¹Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany,
²Department Biology, Universita’ di Roma Tor Vergata, Rome, Italy

Keywords: anakoinosis, shear stress, DNA gels, gold nanorods, Hodgkin’s lymphoma, acute lymphoblastic leukemia, non-small cell lung cancer, graft versus host disease

Editorial on the Research Topic

Anakoinosis: An Innovative Anticancer Therapy Targeting the Aberrant Cancer Tissue Homeostasis

TARGETING THE ABERRANT CANCER TISSUE HOMEOSTASIS

The aim of anakoinosis is “tissue editing,” meaning that bioactive, regulatory acting principles are combined to re-establish tissue homeostasis at primary and metastatic tumor sites by communicatively reprogramming tumor tissue and cell recruitment (Heudobler et al., 2019). Pro-anakoinotic therapies combine regulatorily active drugs, even those with poor or no monoactivity, and may positively supplement classic targeted therapies, as exemplified in relapsed or refractory (r/r) classic Hodgkin’s lymphoma (cHL) with the successful introduction of a target of rapamycin (mTor) inhibitor (Heudobler et al., 2018a; Lüke et al.).

This Research Topic highlights differential clinical outcome characteristics in three histologically completely different neoplasia as a response to “tissue editing” when treated either with pro-anakoinotic approaches (in case of r/r cHL and r/r non-small cell lung cancer, NSCLC) or accidentally initiated by severe fungal infection and reduced intensity induction chemotherapy in acute lymphoblastic leukemia (ALL) (Lüke et al.; Lüke et al.; Heudobler et al.). The clinical responses outline the possibility to specifically activate unique tumor tissue dynamics in response to pro-anakoinotic effectors, either by combining differently acting biomodulatory drugs, or associating DNA damage with fungal infection.

DNA damage response following “one shot” chemotherapy in ALL seems to serve as a homeostatic trigger in the case of parallel fungal infection, presumably supervising and amplifying immunological response by the innate immune system, thereby preventing both early relapse and persistence of minimal residual disease, as indicated by long-term continuous complete remission in both described ALL cases (Lüke et al.).

In r/r NSCLC, explorative studies of the randomized trial provide strong hints that pre-treatment with combined biomodulatory therapy may be the basis for successful consecutive immune checkpoint inhibitor (ICPi) therapy: even though the progression-free survival rate of the biomodulatory treatment arm is significantly inferior to that of the ICPi arm, it, however, exerts tissue modifications that render successive ICPi more efficacious. These results stimulate the hypothesis that the addition of ICPi to the biomodulation could be beneficial (Heudobler et al.).

The immune-modulatory acting MEPED schedule for r/r cHL resulted in pivotal outcomes in six cases. Whether a patient is frail and does not respond to reduced standard first-line therapy, or patients are r/r after autologous hematopoietic-stem-cell transplant (autoHSCT), or even allogeneic...
Hematopoietic-stem-cell transplant (alloHSCT), MEPED may induce complete PET negative remission. The remissions could be maintained by alloHSCT. But even after discontinuation of MEPED in a frail patient, CR continued without any HSCT. Like in NSCLC, a possible beneficial supplementation of the immune-modulatory schedule could be ICPi therapy (Lüke et al.).

**NOVEL TECHNICAL APPROACHES TO STUDY THE BIOLOGICAL BASIS OF ANAKOINOSIS FOR SUSTAINABLE DRUG DEVELOPMENT**

The use and development of pro-anakoinotic therapies are not restricted to neoplasia. Reprogramming of dysregulated homeostatic pathways, stress response, autophagy, redox and metabolic pathways, and of homeostatic immune regulatory circuitries is generally of pivotal interest, irrespectively of the origin of disease (Kumari et al.; Heudobler et al., 2019).

A comprehensive overview of metabolic changes mediating homeostatically dysbalanced immunologic response during graft versus host disease (GVHD) has been given by the group of Kumari et al. The large series of dysregulated metabolites in GVHD suggest that pro-anakoinotically active drug combinations could contribute to improve or inhibit GVHD in addition to established targeted therapies. In mouse GVHD, for example, the nuclear receptor agonist rosiglitazone may prevent GVHD, an approach that should be studied further in context with additional biomodulators (Song et al., 2012; Heudobler et al., 2018b).

Besides therapeutic modulation of cell metabolism, immune response, or tumor-associated inflammation in neoplasia, as exemplified in cHL, NSCLC, and ALL or GVHD, reprogramming the mechanical properties of tumor and adjacent stromal cells may be an important new therapeutic direction (Favero et al.; Lüke et al.; Lüke et al.; Heudobler et al.). *In vitro* studies by Del Favero identify novel biological paths induced by bio-physical circumstances, such as shear stress, and give a first hint on how to target respective biologic structures for reprogramming tumor functions. Drugs used in pro-anakoinotic schedules, like mTOR inhibitors, e.g., in cHL, may reprogram a response to shear stress, as experimentally shown (Favero et al.; Lüke et al.).

For successful development of combination therapies in the field of anakoinosis, the detailed description of complex tissue functions supporting disease-related, pathophysiologically dysbalanced homeostasis is necessary. This message clearly emerges from the contributions on GVHD, and from the mechanistic analysis of how T24 bladder cancer cells cope with fluid shear stress by modifying their shape (Kumari et al.; Favero et al.). The ALL studies highlight that clinical courses of malignant diseases may cause tissue alterations that render therapeutically accessible homeostatic disbalances previously hidden (Lüke et al.).

Successful pro-anakoinotic biomodulatory therapies in resistant neoplasia of quite different histological origins explicitly emphasize that diagnostics based on methods beyond tumor genomics are of pivotal interest for selecting therapeutical directions to achieve tumor control, particularly in metastatic, refractory disease. This would give a logical framework that allows for selecting drug combinations among the huge amount of available bioactive drugs, and for further pharmacological drug development (Muqaku et al., 2017; Lattuada et al.; Heudobler et al., 2018a).

Development and evaluation of biomodulatory drugs is already ongoing (Lattuada et al.; Baer-Dubowska et al., 2021). Dihydrotanshinone, a naturally occurring compound has been presented in the Research Topic as an inhibitor of hepatocellular carcinoma (HCC) growth by suppressing the JAK2/STAT3 pathway. Systemic therapy of non-resectable HCC still represents a field of medical need (Hu et al.).

A novel technology for the evaluation of systems biological drug interactions, relevant for anakoinosis research, has been presented by Lattuada et al. In the future, DNA-gels could be helpful for studying resetting cellular dysregulated homeostasis in disease, particularly in cancer, including immune activation, inflammation control, or trans-differentiation processes of malignant cells within their cellular environments. As a preclinical platform for evaluating novel drug combinations with pro-anakoinotically active drugs, 3D tissue-like DNA-gels could be implemented, incorporating cell spheroids for the assembly of a novel kind of cellular matrix (Lattuada et al.).

Gold nanorods, currently studied as potential therapeutics in photothermal therapies, may also contribute to evaluating pathophysiologiy in tumor tissues, and as such the impact on tissue homeostasis, by identifying specific binding sites of gold nanorods in single-cell compartments (Liao et al.).

In summary, this research topic provides a novel clinical collection of pro-anakoinotic approaches modifying dysregulated homeostasis in quite different ways for long-term tumor control or even healing of refractory tumor disease. Hopefully, pre-clinical *in vitro* test systems, as indicated by the Research Topic, may promote the exploration of biomodulatory drugs derived from different pharmacological tools for designing pro-anakoinotically acting combination therapies, particularly for overcoming therapeutic problems with refractory neoplasia and complex non-malignant diseases associated with tissue dysregulated homeostasis (Kumari et al.; Lüke et al.; Lüke et al.; Heudobler et al.; Vogt et al., 2006).

**AUTHOR CONTRIBUTIONS**

DH, AR, and LG wrote the manuscript. All authors revised the manuscript critically, approved the final manuscript, and agreed to be accountable for all aspects of the manuscript.
REFERENCES

Baer-Dubowska, W., Narożna, M., Krajka-Kuźniak, V., and Violetta (2021): Anti-Cancer Potential of Synthetic Oleanolic Acid Derivatives and Their Conjugates with NSAIDs. In: Molecules 26 (16), S. 4957. doi:10.3390/molecules26164957

Heudobler, D., Rechenmacher, M., Lüke, F., Vogelhuber, M., Pukrop, T., Herr, W., et al. (2018b). Peroxisome Proliferator-Activated Receptors (PPARγ) Agonists as Master Modulators of Tumor Tissue. Int. J. Mol. Sci. 19 (11). doi:10.3390/ijms19113540

Heudobler, D., Lüke, F., Vogelhuber, M., Klobuch, S., Pukrop, T., Herr, W., et al. (2019): Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going beyond Apoptosis Induction, Front. Oncol. 9, S. 1408. doi:10.3389/fonc.2019.01408

Heudobler, D., Rechenmacher, M., Lüke, F., Vogelhuber, M., Klobuch, S., Thomas, S., et al. (2018a): Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis, Front. Pharmacol. 9, S. 1357. doi:10.3389/fphar.2018.01357

Muqaku, B., Eisinger, M., Meier, S. M., Tahir, A., Pukrop, T., Haferkamp, S., et al. (2017): Multi-omics Analysis of Serum Samples Demonstrates Reprogramming of Organ Functions via Systemic Calcium Mobilization and Platelet Activation in Metastatic Melanoma. Mol. Cell Proteomics 16 (1), S. 86–99. doi:10.1074/mcp.M116.063313

Song, E. K., Yim, J. M., Yim, J. Y., Song, M. Y., Rho, H. W., Yim, S. K., et al. (2012): Rosiglitazone Prevents Graft- Versus-Host Disease (GVHD). Transpl. Immunol. 27 (2-3), S. 128–137. doi:10.1016/j.trim.2012.09.001

Vogt, T., Coras, B., Hafner, C., Landthalser, M., and Reichle, A. (2006): Antiangiogenic Therapy in Metastatic Prostate Carcinoma Complicated by Cutaneous Lupus Erythematosus. Lancet Oncol. 7 (8), S. 695–697. doi:10.1016/ S1470-2045(06)70798-7

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Heudobler, Reichle and Ghibelli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.